# LEAP-007 (NCT03829332)

> Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)

No report yet. It can be ordered.

- Drugs tested: lenvatinib plus pembrolizumab
- Indication: PD-L1-positive treatment-naïve metastatic non-small cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03829332
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Non-small Cell Lung Cancer
- Interventions: Pembrolizumab; Lenvatinib; Placebo for lenvatinib
- Enrollment: 623
- Primary outcome: Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
- Primary outcome: Overall Survival (OS)

## Indexed commentary on LEAP-007 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 6 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=leap-007-nct03829332